Skip to main content

Biotech funding bill hits Senate

After linkurl:clearing;https://www.the-scientist.com/blog/display/54608/ the House of Representatives in April, a bill meant to extend the life of programs that stimulate innovation at linkurl:small biotech companies;https://www.the-scientist.com/blog/display/54816/ has finally found its way onto the floor of the Senate. The Senate Committee on Small Business and Entrepreneurship linkurl:passed the bill,;https://sbc.senate.gov/press/record.cfm?id=301536& which tacks on 14 years to the lifespans of

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
After linkurl:clearing;https://www.the-scientist.com/blog/display/54608/ the House of Representatives in April, a bill meant to extend the life of programs that stimulate innovation at linkurl:small biotech companies;https://www.the-scientist.com/blog/display/54816/ has finally found its way onto the floor of the Senate. The Senate Committee on Small Business and Entrepreneurship linkurl:passed the bill,;https://sbc.senate.gov/press/record.cfm?id=301536& which tacks on 14 years to the lifespans of both the Small Business Innovation Research (SBIR) and the Small Business Technology Transfer Research (STTR) programs, yesterday (July 30). Both programs, which aim to encourage the development and commercialization of products and technologies by small businesses, were due to sunset this September. The SBIR program granted more than $2 billion to start-ups last year. The bone of contention in the bill has been a clause stating that businesses where greater than 50 percent of stock is held by venture capital investors are still eligible for SBIR awards. The linkurl:Small Business Administration,;https://www.the-scientist.com/blog/display/54441/ which manages the programs through 11 federal agencies including the Department of Health and Human Services and the National Science Foundation, had resisted the provision. Current guidelines prohibit such companies from receiving SBIR grants. A compromise clause states that ten SBIR federal agencies can award up to 8 percent of their SBIR funds to these firms, and the National Institutes of Health can award up to 18 percent of its SBIR funds to such companies. Another compromise struck in the Senate committee involved the dollar amounts of SBIR grants. Where the linkurl:House version;https://thomas.loc.gov/cgi-bin/bdquery/z?d110:h.r.05819: indicated a raise in Phase I SBIR grants from $100,000 to $300,000 and a raise in Phase II grants from $750,000 to $2.2 million, the Senate committee's version scaled back those increases to $150,000 and $1 million for Phase I and II grants, respectively. The bill now goes before the full Senate and will return to the House so legislators there can review the changes.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Related articles background image
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad
Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

bioxcell
Scientist reviewing cellular and molecular data on a computer in a laboratory.

Building Translation-Ready Biomarkers with Connected Workflows

Danaher Logo

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays